Long QT syndrome type 3: Clinical Trials

1 trial for Long QT syndrome type 3, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Terminated 1

Follow Long QT syndrome type 3: new trials by email Literature Review of Long QT syndrome type 3 trials Research Report on Long QT syndrome type 3

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
Eleclazine, Eleclazine placebo - Long QT Syndrome Type 3
Phase 3TerminatedGilead Sciences412014-12-172018-01-12

Narrower conditions

Death, Sudden, Cardiac (1)  ·  Long QT Syndrome (1)

Broader conditions

Arrhythmias, Cardiac (1)  ·  Cardiac Conduction System Disease (1)  ·  Cardiovascular Abnormalities (1)  ·  Cardiovascular Diseases (1)  ·  Congenital Abnormalities (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Death (1)  ·  Death, Sudden (1)  ·  Heart Arrest (1)  ·  Heart Defects, Congenital (1)  ·  Heart Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

eleclazine (1)

Sponsors

Gilead Sciences (1)

Countries

Canada (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  United Kingdom (1)  ·  United States (1)

NIH funding

2014 (1)